Cannabis Use Disorder Clinical Trial
Official title:
Effects of THC on Alcohol Consumption and Neural Correlates of Reward
Alcohol and cannabis are often used together such that their effects overlap, but little is known about the neural mechanisms that underlie simultaneous use. High doses of THC have not been well-studied in the laboratory, and it is unclear how high doses of THC may impact alcohol consumption patterns. The proposed study will explore the effects of oral THC (20mg dronabinol) vs. placebo on neural reward, alcohol self-administration and naturalistic co-use patterns.
Participants will undergo a screening assessment, baseline session and two laboratory visits. The laboratory visits will involve an MRI scan and the opportunity to consume alcohol in our BAR lab. Prior to the MRI, participants will consume, a placebo (0mg) or high (20mg) dose of oral THC (dronabinol). Visits will be separated by 7 to 14 days. Dronabinol is an FDA-approved product that will be dispensed by our on-campus pharmacy ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT04139668 -
Vivitrol Treatment for Cannabis Use Disorder
|
Phase 2 | |
Completed |
NCT01656707 -
Adaptive Treatment for Adolescent Cannabis Use Disorders
|
N/A | |
Completed |
NCT03204305 -
Brain Imaging of Cannabinoid Receptors
|
Early Phase 1 | |
Completed |
NCT05005013 -
A Teleheath tDCS Approach to Decrease Cannabis Use
|
N/A | |
Recruiting |
NCT05292547 -
Repetitive Transcranial Magnetic Stimulation to People With Cannabis Use Disorder (SToP-C-rTMS x CUD)
|
N/A | |
Completed |
NCT02932215 -
Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder
|
Phase 1 | |
Completed |
NCT03430050 -
Progesterone for Cannabis Withdrawal
|
Early Phase 1 | |
Withdrawn |
NCT03629106 -
Effects of Cannabis Abstinence on Symptomology and Cognition in Bipolar Disorder
|
N/A | |
Completed |
NCT03334721 -
Gabapentin for Bipolar & Cannabis Use Disorders
|
Phase 2 | |
Recruiting |
NCT04721353 -
Reducing Cannabis Overuse With Prazosin
|
Phase 4 | |
Completed |
NCT03718520 -
The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
|
||
Completed |
NCT03624933 -
Effects of Cannabis Abstinence on Symptoms and Cognition in Depression
|
N/A | |
Recruiting |
NCT05836207 -
Rewards for Cannabis Abstinence-study
|
N/A | |
Not yet recruiting |
NCT06114212 -
Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder
|
N/A | |
Recruiting |
NCT05855668 -
Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment
|
N/A | |
Recruiting |
NCT04517474 -
Comparing the Spanish Version of CANreduce With or Without Psychological Support and Treatment as Usual, Reducing Cannabis Use.
|
N/A | |
Recruiting |
NCT05885542 -
SCORE Emerging Adult Cannabis Use & Stress
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06085222 -
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
|
Phase 1 | |
Completed |
NCT03056482 -
Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)
|
Phase 4 |